Bio-Techne's Wild Ride: Uncertainty and Market Swings

Bio-Techne stock plunges after a cautious outlook at the Baird Global Healthcare Conference, citing a decline in the U.S. academic market and biotech funding uncertainties. Despite growth in pharma and China, investors are spooked by the company's slow approach amidst market jitters and a nearly 30% year-to-date drop. Is this just another swing in Bio-Techne's volatile year, or a sign of deeper troubles ahead? Hosted on Acast. See acast.com/privacy for more information.